First Biologic for Eosinophilic COPD Cuts Flare-Ups by 21%
The U.S. Food and Drug Administration (FDA) has approved mepolizumab (Nucala) as an add-on treatment for adults with chron...
Continue with Facebook
Sign up with your email
Become a member to get even more